Gedatolisib combined with fulvestrant, with or without palbociclib, significantly improved PFS in HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. The triplet regimen reduced ...

Invikafusp alfa demonstrated significant antitumor activity in TMB-H and MSI-H tumors resistant to immune checkpoint blockade, with ORRs ranging from 20.5% to 33.3%. The trial's safety profile was ...

Faeth Therapeutics today announced results from the international DICE trial, a randomized phase 2 study of sapanisertib ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...

Researchers have discovered a protein system that helps explain why some colorectal cancer patients don’t respond to ...

Dr. Simsek began by emphasizing that their group had previously shown that CD8+ T cells expressing PD-1 but lacking TIM-3 or LAG-3 are associated with improved clinical outcomes to anti–PD-1 ...

In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of ...

PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic ...

BERLIN -- Almost half of patients with advanced ALK -positive non-small cell lung cancer (NSCLC) have lived 7 years or longer ...

TUB-040 demonstrated robust clinical activity with a favorable safety profile and excellent tolerability in biomarker-unselected, heavily pre-treated PROC patients At data-cut-off on September ...

BRAFTOVI + MEKTOVI continued to show a substantial median overall survival benefit of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer after ...

Young female patients had a mean baseline EF of 58.3 compared with 75 for older male patients. Additionally, emotional function scores varied by disease type. When divided by cancer type and sex, the ...